



Evoked Pharma to Participate in the H.C. Wainwright BIOCONNECT Virtual Conference

January 4, 2022

SOLANA BEACH, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Evoked Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (G.I.) diseases, today announced that the Company will participate in the H.C. Wainwright BIOCONNECT Conference occurring virtually on January 10 – 13, 2022. Management's presentation will be available on the conference [website](#) beginning at 7:00 a.m. ET on January 10, 2022.

Investors participating in the conference who would like to schedule a one-on-one meeting with Evoked's management may do so by contacting H.C. Wainwright representative or Daniel Kontoh-Boateng at dboateng@dkbpartners.net.

About Evoked Pharma, Inc.

Evoked is a specialty pharmaceutical company focused primarily on the development of drugs to treat GI disorders and diseases. The company developed, commercialized and markets GIMOTI, a nasal spray formulation of metoclopramide, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in adults.

Diabetic gastroparesis is a GI disorder affecting millions of patients worldwide, in which the stomach takes too long to empty its contents resulting in serious GI symptoms as well as other systemic complications. The gastric delay caused by gastroparesis can compromise absorption of orally administered medications. Prior to FDA approval to commercially market GIMOTI, metoclopramide was only available in oral and injectable formulations and remains the only drug currently approved in the United States to treat gastroparesis. Visit www.EvokedPharma.com for more information.

Follow GIMOTI on Facebook: <https://www.facebook.com/Gimoti-metoclopramide-nasal-spray-104672345100289>

Follow Evoked Pharma on Facebook: <https://www.facebook.com/Evoked-Pharma-Inc-131313647029724>

Follow Evoked Pharma on LinkedIn: <https://www.linkedin.com/company/evoked-pharma/>

Safe Harbor Statement

Evoked cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "contemplates," "believes," "estimates," "predicts," "potential" or "continue" or the negatives of these terms or other similar expressions. These statements are based on the company's current beliefs and expectations. These forward-looking statements include statements regarding: potential future prescribing trends for GIMOTI based on this survey of GIs and PCPs or Evoked's marketing efforts; and Evoked's commercialization plans, including its plans to increase awareness and access to GIMOTI. The inclusion of forward-looking statements should not be regarded as a representation by Evoked that any of its plans will be achieved. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in Evoked's business, including, without limitation: Evoked's and EVERSAN's ability to successfully drive market demand for GIMOTI; the results of the ATU survey may not predict prescribing trends by doctors or acceptance by patients, and are not intended to reflect or imply actual prescriptions or sales to date; Evoked's ability to obtain additional financing as needed to support its operations; the COVID-19 pandemic may continue to disrupt Evoked's and EVERSAN's business operations impairing the ability to commercialize GIMOTI and Evoked's ability to generate any product revenue; Evoked's dependence on third parties for the manufacture of GIMOTI; Evoked is entirely dependent on the success of GIMOTI; inadequate efficacy or unexpected adverse side effects relating to GIMOTI that could result in recalls or product liability claims; and other risks and uncertainties detailed in Evoked's prior press releases and in the periodic reports it files with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Evoked undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

Investor Contact:
Daniel Kontoh-Boateng
DKB Partners
Tel: 862-213-1398
dboateng@dkbpartners.net



Source: Evoke Pharma, Inc.